ALEC vs CHRS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALEC's Advanced Deterministic Scorecard reveals significant financial distress: a Piotroski F-Score of 4/9 indicates weak operational health, and the absence of an Altman Z-Score (with a Debt/Equity of 1.18 and negative ROE/ROA) raises bankruptcy risk concerns. Despite a recent 1Y return of +53.9%, the stock trades at extreme valuation multiples (Price/Sales 11.54, Price/Book 7.91) with no profitability, negative earnings, and a staggering -88.5% YoY revenue decline. Insider selling of $0.49M over six months, including large sales by top executives, signals poor confidence. The analyst consensus of 'hold' reflects cautious optimism, but the fundamental deterioration and lack of sustainable value drivers suggest limited upside.
CHRS shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALEC vs CHRS: Head-to-Head Comparison
This page compares Alector, Inc. (ALEC) and Coherus Oncology, Inc. (CHRS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.